Emily Daugherty, MD, University of Cincinnati Medical Center/College of Medicine, Cincinnati, OH, explains the rationale, study design, and results of the FAST-01 trial (NT04592887), which investigated the use of FLASH radiotherapy for bone metastases in the extremities and assessed workflow feasibility, pain response, and toxicity. FLASH radiotherapy delivers ultra-high doses of radiation, and has previously been shown to cause less tissue damage with a similar efficacy against tumour cells in preclinical studies. Findings of the FAST-01 trial were that FLASH radiation is safe and feasible in a clinical setting, with minimal adverse effects. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
